Table 1.
Patient characteristics.
| Characteristics | All evaluable patients (n = 84) | Primary RP (n = 71) | Primary EBRT (n = 13) |
|---|---|---|---|
| Age (years) Median [range] |
65.4 [53.0–84.7] | 65.1 [55.3–79.9] | 70.8 [53–84.7] |
| Time from primary treatment to PET/MRI (months) Median [range] |
48 [3–163] | 47 [3–163] | 54 [36–126] |
| PSA (ng/mL) at time of PET/MRI | 0.7 [0.2–12.9] | 0.6 [0.2–11.0] | 5.2 [2.1–12.9] |
| Median [range] | |||
| PSAdt (months)* | 7.6 [1.2–52] | 7.7 [1.5–52] | 7.2 [1.2–14.1] |
| PSA < 1.0 ng/mL, n (%) | 48 (57.1) | 48 (67.6) | 0 (0) |
| PSA ≥ 1.0 ng/mL, n (%) | 36 (42.9) | 23 (32.4) | 13 (100) |
| Gleason grade group** | |||
| Grade group 1, n (%) | 1 (1.2) | 1 (1.4) | 0 (0) |
| Grade group 2, n (%) | 24 (28.6) | 21 (29.6) | 3 (23.1) |
| Grade group 3, n (%) | 30 (35.7) | 26 (36.6) | 4 (30.8) |
| Grade group 4, n (%) | 14 (16.7) | 11 (15.5) | 3 (23.1) |
| Grade group 5, n (%) | 15 (17.9) | 12 (16.9) | 3 (23.1) |
| Salvage treatment: | |||
| ePLND, n (%) EBRT, n (%) RP, n (%) Endocrine, n (%) |
27 (32.1) 24 (28.6) 1 (1.2) 22 (26.1) |
25 (35.2) 24 (33.8) 0 (0) 10 (14.1) |
2 (15.4) 0 (0) 1 (7.7) 12(92.3) |
EBRT, external beam radiation therapy; ePLND, extended pelvic lymph node dissection; RP, radical prostatectomy. *PSAdt from the subgroup of all patients in whom this variable could be calculated (n = 57 overall, n = 48 primary RP patients, n = 9 EBRT patients). **Gleason score is from histopathology after RP if available (n = 69), otherwise from diagnostic biopsies prior to primary treatment (n = 15).